In Vitro Oncology Services

In vitro oncology work answers the questions that must be settled before an animal study is justified. Whether a compound is active against the intended tumor type, at what concentration, through what mechanism, and in combination with what else are all resolvable in culture at a fraction of the cost and timeline of an in vivo program. A compound entering an efficacy study without that groundwork frequently fails for reasons a two-week assay would have predicted.

Altogen Labs provides IC50 determination and drug efficacy testing across validated human cancer cell lines, cell proliferation and viability assays, combination drug studies and synergy testing, caspase-based apoptosis screening, NCI-60 panel screening, and ELISA and cell-based assay development.

Altogen Labs has run cell-based screening and potency programs for pharmaceutical, biotechnology, and academic clients, including compound series evaluated from first cytotoxicity through to xenograft efficacy within the same facility. Company scientists have published preclinical cytotoxicity and antitumor activity data in the peer-reviewed literature.

Potency and selectivity

IC50 determination establishes the concentration at which a compound inhibits a defined biological readout by half, and is the foundational measurement for any small molecule oncology program. Its usefulness depends entirely on how it was generated. Exposure duration, seeding density, assay readout, and the concentration range tested all shift the resulting value, which is why an IC50 quoted without its assay conditions carries limited information.

Altogen Labs defines these parameters per project and holds them constant across the cell lines being compared, so a potency difference between lines reflects biology rather than assay drift. Selectivity is assessed by running the same assay across a panel spanning the intended indication and appropriate comparator histologies, and where relevant against non-transformed lines, establishing a therapeutic window in culture before the question is taken in vivo.

For assay design or a costed screening cascade, request a quote.

Mechanism of cell death

A reduction in viable cell number does not distinguish a compound that kills cells from one that arrests their division, and the two have different implications for dosing schedule and combination strategy. Proliferation and viability assays separate cytotoxic from cytostatic activity by measuring metabolic activity, membrane integrity, and cell number across a time course rather than at a single endpoint.

Caspase-3 and caspase-7 activation establishes whether cell death proceeds through apoptosis, which is informative mechanistically and because apoptotic and non-apoptotic death differ in their immunological consequences. Cell cycle analysis identifies the phase at which an arresting compound acts, which frequently predicts which combination partners will be synergistic and which antagonistic.

Combination and synergy

Most oncology therapeutics reach patients as part of a combination, yet combination behavior is rarely predictable from single-agent activity. Two compounds of comparable potency can be synergistic, additive, or frankly antagonistic depending on mechanism and on the sequence in which they are given.

Combination studies address this through matrix designs in which both agents are titrated across a concentration grid, generating a response surface from which interaction is quantified by established synergy models rather than asserted from a single ratio. Sequence-dependent designs test whether administering one agent before the other alters the outcome, which is common where the first modulates a pathway on which the second depends. Establishing this in culture before committing to an in vivo combination arm avoids the most expensive form of negative result.

Applied examples

Model selection for an efficacy study. A candidate compound is profiled for IC50 across a panel of lines spanning the intended indication, and the two most sensitive and one resistant line are carried forward as xenograft models, so the in vivo study includes a built-in negative control rather than testing only where activity is expected.

Distinguishing arrest from kill. A compound reducing viable cell number by seventy percent at seventy-two hours is assessed by caspase activation and by washout, establishing that the effect is reversible cytostasis rather than cell death, which changes the dosing schedule taken into the animal study from intermittent to continuous.

Combination triage. Three candidate partners for a targeted agent are tested in matrix format, identifying one synergistic, one additive, and one antagonistic pairing, so that only the synergistic combination consumes an in vivo arm.

From culture to animal studies

In vitro results inform in vivo design directly. Lines demonstrating sensitivity in culture become candidate models for cell line derived xenograft studies, with the same line used in both settings so the comparison is meaningful. Concentration ranges established in vitro inform dose selection in in vivo pharmacology. Mechanistic readouts validated in culture become the pharmacodynamic endpoints for the in vivo study. Where three-dimensional or primary material is more representative than a monolayer, work can be transferred to patient-derived platforms.

Assay conduct and data reporting

Assay conditions, controls, replicate structure, acceptance criteria, and analysis method are specified before work begins. Curve fitting model and the criteria for accepting or rejecting a fit are stated rather than left implicit, since these choices materially affect a reported potency value. Cell line identity is confirmed and contamination control applied routinely. Raw data are reported alongside analyzed results so that a client can re-derive any value independently.

Send compound and indication details, or request a quote.